BRAF and colorectal carcinoma: The different response rates to BRAF V600E‐targeted drugs between BRAF V600E‐mutated melanoma and CRC, and the differential expression pattern of HSPA8 and MYC were consistent with our findings (Figure S3D–F, Supporting Information).